Does Enovis (ENOV) Have the Potential to Rally 77.33% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 77.3% in Enovis (ENOV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Enovis Corporation (ENOV) Q2 2025 Earnings Call Transcript
Enovis Corporation (NYSE:ENOV ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Damien McDonald - CEO & Director Kyle William Rose - Vice President of Investor Relations Phillip Benjamin Berry - Senior VP & CFO Conference Call Participants Caitlin Cronin - Canaccord Genuity Corp., Research Division Dane M. Reinhardt - Robert W.
Enovis (ENOV) Beats Q2 Earnings and Revenue Estimates
Enovis (ENOV) came out with quarterly earnings of $0.79 per share, beating the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $0.62 per share a year ago.
Enovis Corporation (ENOV) Q1 2025 Earnings Call Transcript
Enovis Corporation (NYSE:ENOV ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Kyle Rose - Vice President of Investor Relations Matthew Trerotola - Chair and Chief Executive Officer Ben Berry - Chief Financial Officer Conference Call Participants Vik Chopra - Wells Fargo Vijay Kumar - Evercore ISI Robert Marcus - JPMorgan Dane Reinhardt - Baird Danielle Antalffy - UBS Russell Yuen - William Blair Young Li - Jefferies Operator Hello, everyone, and welcome to the Enovis Corporation Q1 2025 Results Call. My name is Ezra, and I will be your coordinator today.
Enovis (ENOV) Q1 Earnings and Revenues Surpass Estimates
Enovis (ENOV) came out with quarterly earnings of $0.81 per share, beating the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $0.50 per share a year ago.
Enovis Continues To Languish Despite Decent Financial Results
Enovis shares have continued to languish despite on-target financial performance, with Q4'24 results meeting expectations and featuring double-digit growth in its Reconstructive business. Enovis' Recon business outperformed its larger rivals in Q4, with double-digit growth in global hips and knees and double-digit growth in U.S. knees as well. Uncertainty from an unexpected CEO transition and potential 2025 tariffs only add to market hesitation.
Enovis Corporation (ENOV) Q4 2024 Earnings Call Transcript
Enovis Corporation (NYSE:ENOV ) Q4 2024 Results Conference Call February 26, 2025 8:30 AM ET Company Participants Kyle Rose - Vice President of Investor Relations Matt Trerotola - CEO & Chairman Ben Berry - Senior VP & CFO Conference Call Participants Vic Chopra - Wells Fargo Vijay Kumar - Evercore ISI Robbie Marcus - JPMorgan Jeff Johnson - Baird Brandon Vazquez - William Blair Danielle Antalffy - UBS Mike Matson - Needham & Company Caitlin Cronin - Canaccord Jason Wittes - ROTH Operator Good day, and welcome to the Enovis Fourth Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode.
Enovis (ENOV) Q4 Earnings and Revenues Surpass Estimates
Enovis (ENOV) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.92 per share. This compares to earnings of $0.79 per share a year ago.
Zacks Industry Outlook Enovis, Omnicell and Phreesia
Enovis, Omnicell and Phreesia have been highlighted in this Industry Outlook article.
3 Medical Info Systems Stocks to Buy as Stargate AI Drives Industry Prospects
Zacks Medical Info Systems industry stocks like Enovis, Omnicell and Phreesia are expected to gain from the GenAI wave.
Enovis Corporation: Reasonably Valued With Caveats
Medical device concern Enovis Corporation's Q3 results were released on November 6th, showing positive financial performance and future growth prospects. Analysts, including Wells Fargo and Needham, reiterated Buy ratings post earnings with price targets ranging from $62 to $75 per share. The company's growth is benefiting from a recent acquisition, and the stock appears reasonably valued with some caveats.
Enovis (ENOV) Upgraded to Buy: Here's Why
Enovis (ENOV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
